Regulatory lawsuits weigh on Hims & Hers Health stock amid weak momentum

Traders Union
All News
Stocks
Hims & Hers Health drops 1.68% today

Highlights

Hims & Hers Health faces regulatory action from the FTC, California, and Utah over allegations of improper health data sharing, premature prescription billing, and difficult subscription cancellations.
A securities class action lawsuit has been filed in response to regulatory claims, increasing legal risks and uncertainty for Hims & Hers Health stock.
Shares of Hims & Hers Health trade at $29.3, with short-term selling pressure and high volatility, and are expected to fluctuate between $28.08 to $30.52 in the coming days.

Regulatory lawsuits and leadership shakeup heighten sentiment risk

Hims & Hers Health, Inc. is currently facing a lawsuit filed by the Federal Trade Commission, the People of the State of California through Los Angeles County Counsel, and the Utah Division of Consumer Protection, according to Prnewswire. The complaint alleges that the company improperly shared consumers' health data with third-party advertising platforms, charged customers for prescriptions before medical consultations, and imposed hurdles to subscription cancellation; this has raised significant regulatory and legal risk, weighing on sentiment. In addition, the initiation of a securities class action lawsuit as a direct response to these regulatory allegations further amplifies market uncertainty. Hims & Hers Health, Inc. has also appointed new Chief Medical Officers in the UK and Australia to strengthen its clinical leadership as it expands internationally, according to Finance Yahoo.

Technical indicators diverge as buyers and oscillators signal caution

On the hourly chart, HIMS is trading below the MA-20, but above the MA-50 level, while maintaining a position above the MA-200 on the daily timeframe. Immediate resistance is seen at the Ichimoku Kijun line at $29.67. Momentum signals are mixed: MACD indicates strong buying pressure, though ADX remains neutral and offers no clear trend. RSI is at 48.39 with a Sell reading, Stochastic RSI is in oversold territory, and CCI is neutral. Bull/Bear Power points to intraday buyer dominance with a Buy classification, but the Awesome Oscillator is neutral, reflecting the ongoing indecision and elevated caution due to oscillator divergence.

Sideways trend anticipated amid resistance and downside risk

In the short term, HIMS is expected to trade between $28.08 and $30.52, reflecting typical volatility around current levels. There is a 53% probability of further downside and a 47% chance of an upside move. The baseline outlook anticipates sideways consolidation within this corridor; a bullish scenario would require a decisive break above the $29.67 Kijun resistance, while a move below $28.08 would indicate potential for additional weakness.

Anton Kharitonov, expert at Traders Union, sees heightened risk for Hims & Hers Health given the regulatory lawsuits and class action over data handling and billing practices. Technical indicators remain mixed, with uncertainty dominating short-term sentiment. He notes that upside conviction is lacking unless $29.67 is reclaimed. "Base case is for sideways action until the $29.67 resistance falls — buyers need to prove themselves first."

Earlier, analysts noted that Hims & Hers Health exhibited long-term technical strength despite ongoing litigation risks and margin pressures. The escalation of regulatory actions and initiation of a securities class action now add further uncertainty, making the $29.67 Ichimoku Kijun resistance a crucial level for gauging any potential shift from the current consolidation phase.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.